Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 9, Number 1—January 2003
Research

Cost Effectiveness of a Potential Vaccine for Human papillomavirus

Gillian D. Sanders*Comments to Author  and Al V. Taira*
Author affiliations: *Stanford University, Stanford, California, USA

Main Article

Table 1

Health and economic outcomes of HPV vaccinationa

OutcomeNo vaccinationHPV vaccination
Cost, $
39,682
39,928
Incremental cost, $

246
Life expectancy, yrs
28.785
28.793
Incremental life expectancy, days

2.8
Quality-adjusted life expectancy, yrs
27.720
27.731
Incremental quality-adjusted life expectancy, days

4.0
Incremental cost effectiveness


$/life year

32,066
$/quality-adjusted life year22,755

aHPV, Human papillomavirus.

Main Article

Page created: December 07, 2010
Page updated: December 07, 2010
Page reviewed: December 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external